Media headlines about Celgene (NASDAQ:CELG) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celgene earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.7335240808515 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Celgene Cratering to Four-Year Low Leaves Analysts Split (finance.yahoo.com)
- Celgene Wins One Bull, Loses Another On Revlimid Potential (finance.yahoo.com)
- David's 5 Winning Stocks for a Thinking World: 2 Years Later, Has a Bet on Brains Paid Off? (finance.yahoo.com)
- Analysts Split: Celgene Tilts 'To Greater Risk' On Revlimid Challenges (finance.yahoo.com)
- CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018 (finance.yahoo.com)
A number of equities analysts have issued reports on the company. Cantor Fitzgerald set a $112.00 target price on Celgene and gave the stock a “hold” rating in a report on Tuesday, January 23rd. Argus cut Celgene from a “buy” rating to a “hold” rating in a report on Wednesday. Sanford C. Bernstein raised Celgene from a “market perform” rating to an “outperform” rating and set a $102.00 target price on the stock in a research report on Wednesday. Robert W. Baird reaffirmed a “hold” rating and set a $92.00 price target on shares of Celgene in a research report on Thursday, March 1st. Finally, Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating in a research report on Wednesday, January 31st. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and a consensus price target of $123.35.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.96 by $0.09. Celgene had a return on equity of 72.92% and a net margin of 20.73%. The company had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.47 billion. During the same quarter last year, the company earned $1.68 earnings per share. The firm’s quarterly revenue was up 19.4% on a year-over-year basis. sell-side analysts expect that Celgene will post 7.63 earnings per share for the current fiscal year.
Celgene declared that its board has approved a stock buyback program on Wednesday, February 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
In other news, Director James J. Loughlin sold 9,250 shares of Celgene stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $92.01, for a total value of $851,092.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ernest Mario sold 13,370 shares of Celgene stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $94.49, for a total value of $1,263,331.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,370 shares of company stock worth $4,297,239. Company insiders own 0.95% of the company’s stock.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.